Cited 16 time in
Symptom palliation of hypofractionated radiotherapy for patients with incurable inflammatory breast cancer
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Choi, Hoon Sik | - |
| dc.contributor.author | Jang, Hong Seok | - |
| dc.contributor.author | Kang, Ki Mun | - |
| dc.contributor.author | Choi, Byung-ock | - |
| dc.date.accessioned | 2022-12-26T14:47:52Z | - |
| dc.date.available | 2022-12-26T14:47:52Z | - |
| dc.date.issued | 2019-06-20 | - |
| dc.identifier.issn | 1748-717X | - |
| dc.identifier.uri | https://scholarworks.gnu.ac.kr/handle/sw.gnu/9041 | - |
| dc.description.abstract | BackgroundIncurable inflammatory breast cancer (IBC) patients occasionally suffer from general symptoms such as breast pain, bleeding, ulceration, and discharge, and thus require palliative radiotherapy (RT). Hypofractionated RT has many advantages in palliative settings, but very few studies on IBC have been conducted. This study was conducted to evaluate the effects of hypofractionated RT on symptomatic IBC patients.MethodsTwenty-two patients with IBC who underwent hypofractionated palliative RT between 2010 and 2016 were retrospectively analyzed. RT was performed at a total dose of 42.5-55Gy with 2.5-3Gy per fraction. The treatment effects were evaluated with respect to symptom improvement, tumor response, and treatment-related toxicity.ResultsThe main symptoms that the patients complained of before RT were pain, bleeding, and discharge. According to the percentage of symptom relief compared with pre-RT symptoms, the number of patients with <30, 30-70%, and70% were 2 (9.1%), 7 (31.8%), and 13 (59.1%), respectively. Eighteen (81.8%) patients showed tumor response. No patient experienced grade 3 or higher acute or chronic toxicity during a median follow-up period of 13months. In univariate analysis, symptom type was a significant factor for predicting the degree of symptom relief. Meanwhile, RT field and C-reactive protein increase were significant factors for predicting the incidence of radiation-induced skin toxicity.ConclusionsHypofractionated RT could safely and effectively relieve symptoms among incurable symptomatic IBC patients. | - |
| dc.language | 영어 | - |
| dc.language.iso | ENG | - |
| dc.publisher | BMC | - |
| dc.title | Symptom palliation of hypofractionated radiotherapy for patients with incurable inflammatory breast cancer | - |
| dc.type | Article | - |
| dc.publisher.location | 영국 | - |
| dc.identifier.doi | 10.1186/s13014-019-1320-2 | - |
| dc.identifier.scopusid | 2-s2.0-85067578365 | - |
| dc.identifier.wosid | 000472510500001 | - |
| dc.identifier.bibliographicCitation | RADIATION ONCOLOGY, v.14, no.1 | - |
| dc.citation.title | RADIATION ONCOLOGY | - |
| dc.citation.volume | 14 | - |
| dc.citation.number | 1 | - |
| dc.type.docType | Article | - |
| dc.description.isOpenAccess | Y | - |
| dc.description.journalRegisteredClass | scie | - |
| dc.description.journalRegisteredClass | scopus | - |
| dc.relation.journalResearchArea | Oncology | - |
| dc.relation.journalResearchArea | Radiology, Nuclear Medicine & Medical Imaging | - |
| dc.relation.journalWebOfScienceCategory | Oncology | - |
| dc.relation.journalWebOfScienceCategory | Radiology, Nuclear Medicine & Medical Imaging | - |
| dc.subject.keywordPlus | RADIATION-THERAPY | - |
| dc.subject.keywordPlus | IRRADIATION | - |
| dc.subject.keywordPlus | MANAGEMENT | - |
| dc.subject.keywordPlus | CARCINOMA | - |
| dc.subject.keywordPlus | OUTCOMES | - |
| dc.subject.keywordPlus | HEAD | - |
| dc.subject.keywordAuthor | Inflammatory breast cancer | - |
| dc.subject.keywordAuthor | Palliation | - |
| dc.subject.keywordAuthor | Hypofractionated radiotherapy | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
Gyeongsang National University Central Library, 501, Jinju-daero, Jinju-si, Gyeongsangnam-do, 52828, Republic of Korea+82-55-772-0532
COPYRIGHT 2022 GYEONGSANG NATIONAL UNIVERSITY LIBRARY. ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.
